Join our Whatsapp Community for Daily Price Sheets and News

Veeda Clinical Research Limited Shares Financial Performance & Analysis

Key financial metrics, growth trends, and downloadable reports

Financial Highlights

Market Cap
Current Valuation
₹ 3024
Book Value
Per Share
₹168.67
Total Shares
Outstanding
6,29,99,846

Annual Reports & Financial Statements

Financial YearReport TypePublished DateAction
2026Annual Report31/12/2026Not Available

Financial Data Summary

Veeda Clinical Research Limited Shares is an unlisted company with limited publicly available financial data. Below are the key financial metrics available for analysis.

Valuation Metrics

Market Cap₹ 3024
Current Share Price448
52-Week Range₹ 480 - ₹ 575
Face Value2
Total Shares Outstanding6,29,99,846

Financial Ratios

P/E RatioN/A
P/B Ratio2.85
Return on Equity (ROE)-0.03
Debt to Equity0.25
Book Value168.67

Company Registration Details

CINU73100GJ2004PLC044023
PAN NumberAACCC3633Q
ISIN NumberINE01HQ01026
RTALink Intime India Pvt Ltd.
DepositoryNSDL & CDSL
Lot Size100 Shares

Note: As Veeda Clinical Research Limited Shares is an unlisted company, detailed year-by-year financial data may not be publicly available. The data provided above represents the most recent available financial information.

Key Financial Ratios

P/E Ratio
Price-to-Earnings Ratio
N/A

Near N/A average

ROE
Return on Equity
-0.03

Below average return on shareholder equity

Debt to Equity
Leverage Ratio
0.25

Very low leverage

P/B Ratio
Price-to-Book Ratio
2.85

Above book value

52-Week Range
Price Movement
₹ 480 - ₹ 575

Currently trading near 52-week low

Peer Comparison & Industry Context

Veeda Clinical Research Limited Shares's financial ratios highlight its market position in the N/A sector, though direct peer comparisons may vary based on its business model. The Price-to-Earnings (P/E) ratio of N/A indicates the company is valued conservatively relative to earnings, reflecting market confidence in the company's brand and business performance. The Return on Equity (ROE) of -0.03 shows reasonable use of shareholder funds to generate profits, signaling solid management performance.

Veeda Clinical Research Limited Shares's Debt-to-Equity ratio of 0.25 demonstrates a very conservative financial approach, reducing financial risk. Meanwhile, the Price-to-Book (P/B) ratio of 2.85 suggests the market values the company moderately above its book value, anticipating future revenue growth and continued business performance. These metrics collectively position Veeda Clinical Research Limited Shares as a solid investment with growth potential and good financial stability within its sector.

Interested in Veeda Clinical Research Limited Shares Unlisted Shares?

Get expert guidance on Veeda Clinical Research Limited Shares investment potential based on its financial performance.

Our Blogs

Our blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.

FAQ's

What is the minimum investment required to buy Veeda Clinical Research Limited Shares?

+

The minimum investment for Veeda Clinical Research Limited Shares typically depends on the current market price. With a share price of ₹448, we recommend contacting us for the latest details on minimum investment requirements.

Is KYC mandatory for buying Veeda Clinical Research Limited Shares?

+

Yes, KYC (Know Your Customer) is mandatory for all unlisted share transactions in India. This is a regulatory requirement to prevent money laundering and ensure legitimate transactions. You&ll need to provide identity proof, address proof, PAN card, and bank details.

How long does it take to complete a Veeda Clinical Research Limited Shares share transaction?

+

Once all documentation is complete and verified, the transaction typically takes 2-3 business days for processing and settlement. The shares will be transferred to your demat account within this timeframe after payment confirmation.

What are the risks involved in buying unlisted shares?

+

Investing in unlisted shares involves certain risks including liquidity risk (difficulty in selling quickly), valuation uncertainty, limited regulatory oversight, and potential information asymmetry. However, they also offer the potential for higher returns especially if the company performs well or goes for an IPO.

Can NRIs buy unlisted shares in India?

+

Yes, Non-Resident Indians (NRIs) can invest in unlisted shares in India through the Portfolio Investment Scheme (PIS). However, they need to comply with FEMA regulations and may require special permissions. NRIs should consult with their financial advisors regarding the specific requirements.

How can I track the performance of my Veeda Clinical Research Limited Shares?

+

You can track your Veeda Clinical Research Limited Shares unlisted shares through our portfolio tracking service. We provide regular updates on significant developments, valuation changes, and other important information related to Veeda Clinical Research Limited Shares and other unlisted companies in your portfolio.

WhatsAppContact Us